GENTEX CORP

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

GNTX$19.42-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Shareholders' Investment

For the Three Months Ended September 30, 2026 and 2025

Common StockShares · Common StockAmount · Additional Paid-InCapital · Retained Earnings · Accumulated OtherComprehensiveIncome (Loss) · Total · Equity Attributable to Noncontrolling Interests · Total Shareholders’Investment
BALANCE AS OF JULY 1, 2026	210,708,050	$12,642,483		$1,008,061,267	$1,515,686,310		$1,710,698	$2,538,100,758		$—	$2,538,100,758
Issuance of common stock from stock plan transactions	288,585	17,315		1,196,240	—		—	1,213,555		—	1,213,555
Repurchases of common stock	(5,654,089)	(339,245)		(23,803,716)	(108,416,145)		—	(132,559,106)		—	(132,559,106)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock	—	—		9,636,043	—		—	9,636,043		—	9,636,043
Dividends declared ($0.12 per share)	—	—		—	(24,640,204)		—	(24,640,204)		—	(24,640,204)
Purchase of non-controlling interest in Onkyo joint venture			4,590,123			4,590,123			4,590,123
Net income (1)	—	—		—	90,564,884		—	90,564,884		—	90,564,884
Other comprehensive income (loss)	—	—		—	—		(3,000,926)	(3,000,926)		—	(3,000,926)
BALANCE AS OF SEPTEMBER 30, 2026	205,342,546	$12,320,553		$999,679,957	$1,473,194,845		$(1,290,228)	$2,483,905,127		$—	$2,483,905,127
BALANCE AS OF JULY 1, 2025	219,520,750	$13,171,245		$998,911,809	$1,421,351,763		$(3,396,649)	$2,430,038,168		$599,556	$2,430,637,724
Issuance of common stock from stock plan transactions	434,634	26,078		7,028,233	—		—	7,054,311		—	7,054,311
Repurchases of common stock	(1,003,580)	(60,215)		(4,044,427)	(24,178,827)		—	(28,283,469)		—	(28,283,469)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock	—	—		10,436,395	—		—	10,436,395		—	10,436,395
Dividends declared ($0.12 per share)	—	—		—	(26,274,216)		—	(26,274,216)		—	(26,274,216)
Purchase of additional interest in BioCenturion LLC	—	—		525,301	—		—	525,301		(600,301)	(75,000)
Net income (1)	—	—		—	100,967,910		—	100,967,910		745	100,968,655
Other comprehensive income	—	—		—	—		750,426	750,426		—	750,426
BALANCE AS OF SEPTEMBER 30, 2025	218,951,804	$13,137,108		$1,012,857,311	$1,471,866,630		$(2,646,223)	$2,495,214,826		$—	$2,495,214,826

(1)Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $0 and $81,206 for the three months ended September 30, 2026 and 2025, respectively (see Note 16).

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' INVESTMENT

For the Nine Months Ended September 30, 2026 and 2025

Common StockShares · Common StockAmount · Additional Paid-InCapital · Retained Earnings · Accumulated OtherComprehensiveIncome (Loss) · Total · Equity Attributable to Noncontrolling Interests · Total Shareholders’Investment
BALANCE AS OF JANUARY 1, 2026	215,445,024	12,926,701		1,008,589,267	1,466,046,002		267,754	2,487,829,724		$—	$2,487,829,724
Issuance of common stock from stock plan transactions	1,501,047	90,063		5,136,312	—		—	5,226,375		—	5,226,375
Repurchases of common stock	(11,603,525)	(696,211)		(48,412,143)	(221,079,059)		—	(270,187,413)		—	(270,187,413)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock	—	—		29,776,398	—		—	29,776,398		—	29,776,398
Dividends declared ($0.36 per share)	—	—		—	(75,481,543)		—	(75,481,543)		—	(75,481,543)
Purchase of non-controlling interest in Onkyo joint venture			4,590,123			4,590,123			4,590,123
Net income (1)	—	—		—	303,709,445		—	303,709,445		—	303,709,445
Other comprehensive income (loss)	—	—		—	—		(1,557,982)	(1,557,982)		—	(1,557,982)
BALANCE AS OF SEPTEMBER 30, 2026	205,342,546	$12,320,553		$999,679,957	$1,473,194,845		$(1,290,228)	$2,483,905,127		$—	$2,483,905,127
BALANCE AS OF JANUARY 1, 2025	227,207,472	$13,632,448		$1,010,440,420	$1,450,287,128		$(6,409,341)	$2,467,950,655		$4,149,000	$2,472,099,655
Issuance of common stock from stock plan transactions	1,550,327	93,020		13,245,032	—		—	13,338,052		—	13,338,052
Repurchases of common stock	(9,805,995)	(588,360)		(39,156,090)	(190,706,233)		—	(230,450,683)		—	(230,450,683)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock	—	—		26,596,685	—		—	26,596,685		—	26,596,685
Dividends declared ($0.36 per share)	—	—		—	(79,595,804)		—	(79,595,804)		—	(79,595,804)
Capital contributions, net	—	—		—	—		—	—		442,500	442,500
Fair value of non-controlling interest in EyeLock LLC	—	—		—	—		—	—		656,000	656,000
Purchase of additional interest in EyeLock LLC	—	—		525,301	—		—	525,301		(600,301)	(75,000)
Purchase of additional interest in BioCenturion LLC	—	—		1,205,963	—		—	1,205,963		(4,591,549)	(3,385,586)
Net income (loss) (1)	—	—		—	291,881,539		—	291,881,539		(55,650)	291,825,889
Other comprehensive income	—	—		—	—		3,763,118	3,763,118		—	3,763,118
BALANCE AS OF SEPTEMBER 30, 2025	218,951,804	$13,137,108		$1,012,857,311	$1,471,866,630		$(2,646,223)	$2,495,214,826		$—	$2,495,214,826

(1)Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $539,730 and $470,340 for the nine months ended September 30, 2026 and 2025, respectively (see Note 16).

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.